0
0
London, Apr 16 – In a significant breakthrough, an international research collaboration has identified common genetic changes that could hold the key to understanding why many people with focal epilepsy do not respond to standard treatments.
Focal epilepsy, characterized by seizures starting in a specific brain region, is the most common form of the condition. While antiseizure medications are the first line of defense, a challenging reality remains: nearly one-third of patients, estimated at around 20 million people globally, experience ongoing seizures despite medication. This condition is known as drug-resistant epilepsy.
The new study, jointly spearheaded by scientists at University College London (UCL) and UTHealth Houston, sheds light on this problem by highlighting two specific genetic variants associated with drug resistance. These variants are located in the CNIH3 gene, which influences brain receptors, and the WDR26 gene, involved in various cellular functions.
Published in the journal EBioMedicine, the research involved a large-scale analysis of the genomes of 6,826 individuals with epilepsy. Within this group, over 4,200 suffered from the drug-resistant form. The analysis revealed that individuals carrying the identified variants in CNIH3 or WDR26 had a notably higher likelihood of their epilepsy being unresponsive to commonly prescribed antiseizure drugs.
“These results provide a key insight into why some people have seizures that don’t respond to available drugs,” commented Professor Sanjay Sisodiya from UCL’s Queen Square Institute of Neurology, a lead author on the study.
Costin Leu, Assistant Professor at UTHealth Houston and another key contributor, noted the significance of these genetic markers being relatively common in the general population. He suggested that recognizing these genetic signatures could pave the way for more focused diagnostic testing and the development of targeted therapies in the future.
A crucial aspect of the findings is the potential for early prediction. Since these genetic markers can be identified when epilepsy is first diagnosed, doctors might soon be able to predict the likelihood of drug resistance early on. This could prevent patients from enduring prolonged periods on medications unlikely to work, potentially reducing associated health risks and improving overall quality of life.
This discovery represents a promising advancement towards personalized medicine in epilepsy care, offering hope for better management strategies and improved outcomes for the millions affected by drug-resistant forms of the condition worldwide.
Disclaimer: This news article is based on information provided regarding a study published in EBioMedicine. It is intended for informational purposes only and does not constitute medical advice. Consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
